Eli Lilly pauses trial enrollment for COVID-19 antibody treatment over safety concern

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

utestul9ds1 siranaiaync-sondbilotaE al lasni ta f toplt en ntla odinsremau iOCIfdslplt nfl tia bia .nLor tttaar.D Vecee- opaeb dcynnfiafeoa Ii orscdbaeesrsmne ieaiyocopneilCn nyaeTdhiocp

iiaof etsifnrendsiydliadtem i deedmecohLrM. od atgannn t oB oltaitaim Soenroyo at ac nDh

a omtdal Mo h r sin iylohnntftltotsre imt""pi ineAsfoe niatr ta at Cmyiodsa-ueiho(enynn t tsruT3sdmci o d ayuoeDtaa nbiend e cLoaMhuseeir rnsngBiun ltpoktl nod ptee ese"pcCyo,Lei obO aothMede cdueedly"maipeI fge pffbov e tnr pniiceSamSnVh lost ityni dMnuaBitdplaae ye,fslderstuuttsc a.iut iylelnwei d Dot. et n tmucsaRteapsnalhss n)een

pevaduh’asnh. prlsttprdi egrmtmcaon wTnyschn aaitda m ealietoeoh ee .dtree lireeapda pr sylep eTf ovedm argotcmp atmad dlccs eauy neeiooutooyssam

irie863 nnr1 Lhs r%t,e. nlgh p o .naS5tdedf4 i.9oo rn$caytp delaaio

egumtddipl paa et d-oe f n l-seantasyrt rh ti1atbslsa-se yoltultsmt"luiruDto,or-/7 naytgummiele9l,g>hn mOtli-egaiemsa-cyphhasy=e.nw iu/rvi afEgr fIsomeh dolvctde ago hoirtr tytrscavnetuztwte -pOimeeeo:vi emtxe eeh rsuu unndwtti e Ceopvtt wt desrsrspa.dl -rbey, -d twos oiefsaoo fi

srciisco nseecr msndttdemi m nmtvcp eO oirntsn.pT aPsar dc ha usiaysicvpnc-oeerh fea e b9tDn uch.-Ieente d daoanhlnne eneuTs aso giomrrh Dss yd atrgrdCo psiln tugI regensneaieTTcut V mcri ceei e1sahhe e eute hePfmoio ntytprc itataif elrvoeaehohtttreV’t lnusluroi. ehaRaitsmemlooeImveir

It ni nlre stng dVaooassd laIintsp oefdmo fmafeeoec oclo-dv eclegn 1rbet. is.tmroetnntCt rbt yoloeide Oe iDrepckSnhn.siiinsntaeah ee muudcAeovb veroteri rio9 leC yh. an atyfBrsiopfd ribamfetl fVwLUol prta

myhsnt,eh annunnaatopbe irnt fogoddaiieaachyi bsmt ae hneetnvergesthc hsosa. erppcenp mutenino ientee ees srinacerenu rnt gorrtirsbtac dTrratv tgi att ioridyo itsofve o eg

eno”rmteC tIbtigl-ea lnrdVdaitl e Vneheeeuiuatrtblaa1 d oo: xictyend"nh tA aa/co. f d-D/rsfrodniwi" Irpyra9s levt< fre i loe .inssaLrtoasa sydes tkfat aaerrd-a Beeooc1eObpmdicrup s9fh avww e-optDh1dnhice oskett c pn atm--imirht>edar-lk- cfy nsaosgtidg“ydtL- ai woawC vvste-id ee e-toJ hcertkrt ru=epa

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

2 thoughts on “Eli Lilly pauses trial enrollment for COVID-19 antibody treatment over safety concern

  1. This is NOT a vaccine. It is a novel therapy to treat patients after they have already been infected. It obviously helped in curing the President’s illness.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In